Talens-Mediated Homozygous Ccr5 Delta 32 Mutations Endow Cd4(+) U87 Cells With Resistance Against Hiv-1 Infection

Ai Qing Yu,Yan Ding,Zhi Yong Lu,Yan Zhe Hao,Zhi Ping Teng,Shi Rong Yan,Dong Sheng Li,Yi Zeng
DOI: https://doi.org/10.3892/mmr.2017.7889
IF: 3.423
2018-01-01
Molecular Medicine Reports
Abstract:Since evidence suggests that transplantation of bone marrow stem cells with the C-C chemokine receptor type 5 (CCR5)32/32 genotype may cure patients infected with human immunodeficiency virus (HIV)-1, the present study aimed to reproduce the CCR532 mutation in cluster of differentiation (CD)4(+) U87 cells using genome engineering methods. A modified transcription activator-like effector nucleases (TALENs) technique, combined with homologous recombination for site-specific, size-controlled and homozygous DNA deletions, was used to reproduce the homozygous CCR532 mutation in CD4(+) U87 cells. The results indicated that the frequency of the TALENs-targeted mutation reached 50.4% without any selection, whereas homologous recombination from CCR5 to CCR532 occurred in 8.8% of targeted cells. Notably, a HIV-1 challenge test demonstrated that CCR532/32 CD4(+) U87 cells were resistant to HIV infection. In conclusion, engineered CCR532/32 mutations endowed CD4(+) U87 cells with resistance against HIV-1 infection; this site-specific, size-controlled and homozygous DNA deletion technique was able to induce precise genomic editing, i.e., the deletion or insertion of a predetermined length of DNA sequence at a specific locus throughout the genome.
What problem does this paper attempt to address?